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Objective: The Ross procedure offers good autograft function and low reoperation rates for the neoaortic valve;
however, the rate of conduit dysfunction in the right ventricular outflow tract remains a concern. This study as-
sessed percutaneous pulmonary valve implantation in this setting.
Methods:We retrospectively analyzed outcomes of 12 patients (mean age 28  5 years) referred for percutane-
ous pulmonary valve implantation to treat right ventricle–pulmonary artery conduit failure 11.1 3.3 years after
Ross procedure.
Results: Percutaneous pulmonary valve implantation was feasible in all 12 patients, with no procedural compli-
cations (procedure time 99  16 minutes, fluoroscopy time 21  6 minutes). Right ventricular outflow tract
gradient during catheterization and pulmonary regurgitant fraction on magnetic resonance imaging fell after valve
implantation (gradient 34 6 to 14 3 mmHg, P<.01, regurgitant fraction 20% 6% to 2% 1%, P<.05).
After restoration of right ventricular outflow tract function, indexed right ventricular end-diastolic volume
decreased (91  13 to 78  12 mL $ beat1 $ m2, P<.01) and maximal cardiopulmonary exercise performance
improved (peak oxygen consumption 25.4  2.3 to 30.8  3.0 mL $ kg1 $ min1, P< .01). During follow-up
(18.8  4.6 months), there was 1 device explantation (restenosis). The probabilities of freedom from right ven-
tricular outflow tract reoperation were 100% at 1 year and 90% at 3 years.
Conclusions: Percutaneous pulmonary valve implantation provides an effective transcatheter treatment strategy
to prolong the lifespan of right ventricle–pulmonary artery conduits after the Ross procedure, reducing the reop-
eration burden on patients with aortic valve disease.
CONGENITAL HEART DISEASEThe pulmonary autograft replacement of aortic valve (Ross
procedure)1 represents an attractive surgical option for aortic
valve disease, especially for younger patients. Because it
uses the patient’s own pulmonary valve as an aortic auto-
graft, advantages include a favorable hemodynamic profile,
the potential for adaptive growth,2 and the avoidance of anti-
coagulation therapy and its associated risks.3 In addition, the
autograft function has been shown to be acceptable in sev-
eral studies reporting midterm outcomes for this procedure
in different patient populations.3-7 A major drawback of
this procedure, however, is that the necessary placement of
a conduit from the right ventricle (RV) to the pulmonary ar-
tery (PA) converts ‘‘single-valve disease’’ into ‘‘two-valve
disease.’’ Although the orthotopic positioning of the RV-
PA conduit may provide a reasonable longevity,8 the rate
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cern, with an estimated freedom from reoperation or resteno-
sis (peak RV outflow tract [RVOT] gradient exceeding 30
mm Hg) of only 64% at 6 years in a pediatric cohort.6 We
report our experience with percutaneous pulmonary valve
implantation (PPVI)9,10 as a transcatheter treatment option
for RV-PA conduit dysfunction in this setting.
MATERIALS AND METHODS
Patients
Of the 176 patients who underwent PPVI with the current device design
(January 2003–November 2007), we retrospectively examined the out-
comes of 13 patients who had RV-PA conduit dysfunction after the Ross
procedure. One patient with repaired complex left ventricular outflow tract
obstruction (coarctation with valvular and supravalvular aortic stenosis) was
excluded from the analysis, because PPVI was performed only as part of
a palliative strategy in the context of multiorgan failure. Most of the remain-
ing patients (10/12) had the Ross procedure performed outside our institu-
tions. Clinical indications for PPVI included RV hypertension with
significant RVOT obstruction, significant pulmonary insufficiency, and
RV dilatation or failure as described previously.10
PPVI was performed under general anesthesia at Great Ormond Street
Hospital for Children, The Heart Hospital, and Harley Street Clinic (Lon-
don, UK). The ethics committees at these institutions approved the study
protocol, and written, informed consent was obtained from patients and
parents as appropriate.
Echocardiography
On echocardiography, peak RVOT gradient and RV systolic pressure
(estimated from tricuspid regurgitant jet velocities) were obtained fromgery c July 2009
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CPEX ¼ cardiopulmonary exercise
MRI ¼ magnetic resonance imaging
PA ¼ pulmonary artery
PPVI ¼ percutaneous pulmonary valve
implantation
RV ¼ right ventricle
RVOT ¼ right ventricular outflow tract
continuous-wave Doppler traces (VIVID 7; GE, Medical Systems, Milwau-
kee, Wis). Color flow mapping of the RVOT and branch pulmonary arteries
was used for qualitative grading of the degree of pulmonary regurgitation (0
absent, 1 trivial, 2 mild, 3 moderate, and 4 severe).
Cardiopulmonary Exercise Testing
Ten of 12 patients underwent cardiopulmonary exercise (CPEX) testing
before and early after PPVI (median 20 days after PPVI, range 2–381 days).
The remaining 2 patients did not undergo CPEX testing because of pulmo-
nary hypertension (n¼ 1) and nonmedical reasons (n¼ 1). A ramp protocol
was performed on a mechanically braked bicycle ergometer (ergometrics
ER 900 PC; ergoline GmbH, Bitz, Germany). Peak oxygen consumption
was derived from respiratory gas analysis during CPEX testing.12
Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance imaging (MRI) was performed for 10 of 12
patients before and early after PPVI (median 7 days after PPVI, range 1–364
days). The remaining 2 patients did not undergo cardiac MRI because they
had pacemakers inserted. The MRI scans were performed at 1.5 T (Sym-
phony Maestro Series and Avanto; Siemens Medical Systems, Erlangen,
Germany). Retrospective gated steady-state free-precession cine images
of the heart and arterial flow data with a flow-sensitive gradient echo se-
quence were acquired.12 Thereafter, ventricular volumes, pulmonary and
aortic regurgitant fractions were calculated with the Argus analysis work
package (Siemens Medical Systems).
Follow-up Assessment
During structured follow-up, echocardiographic and chest radiographic
investigations were performed immediately after PPVI and at 1 month, 3
months, 6 months, 1 year, and yearly thereafter. Echocardiography was
used to assess the hemodynamic situation; chest radiography was used to
screen for structural integrity of the stent.The Journal of Thoracic andStatistical Analysis
Data are expressed as mean  SEM unless otherwise specified. Two
paired samples were analyzed with paired Student t tests or Wilcoxon
matched pairs tests as appropriate. Multiple comparisons were performed
with repeated measures analysis of variance and subsequent post hoc anal-
ysis (Bonferroni correction) as appropriate. Probability of freedom from
reintervention was obtained by use of Kaplan–Meier plots. Statistical
testing and data analysis were performed with SPSS version 11 (SPSS
Inc, Chicago, Ill) and GraphPad InStat 3 Demo (Graphpad Software, Inc,
La Jolla, Calif).
RESULTS
Baseline Characteristics
Twelve patients (28  5 years old, 21–98 kg) underwent
PPVI for RV-PA conduit failure 11.1  3.3 years after Ross
procedure (Table 1). The indications for PPVI were predom-
inant RV-PA conduit stenosis in 6 of 12 patients (50%), pre-
dominant conduit regurgitation in 4 of 12 (33%), and mixed
conduit dysfunction in 2 of 12 (17%) (Table 1). The failed
conduits comprised homografts in 11 of 12 cases (92%, first
homograft n ¼ 8, reconstructed first homograft n ¼ 1, sec-
ond homograft n ¼ 2) and a porcine valve conduit in the
remaining case (8%).
In the aortic position, 11 of 12 patients (92%) had the
original autograft in place with no significant incompetence
(median aortic regurgitant fraction 3%, range 0%–17%).
One patient (8%) had a 19-mm St Jude mechanical valve
(St Jude Medical, Inc, St Paul, Minn), which was inserted
because of early autograft failure 1 year after the Ross
procedure.
Procedural Details
PPVIwas successful in 12 of 12 patients (100%; Figure 1),
with no procedural complications (procedure time 99  16
minutes; fluoroscopy time 21  6 minutes). Prestenting
with a bare-metal stent (Max LD; ev3 Endovascular, Inc, Pe-
ripheral Vascular, Plymouth,Minn) was performed in 2 of 12
patients (17%), particularly in the context of early second ho-
mograft failure, 1.5 years and 3.5 years after surgery.TABLE 1. Clinical characteristics of patients with percutaneous pulmonary valve implantation after Ross procedure
Case Sex Age (y) Time since Ross (y) RV outflow tract RV-PA conduit lesion
1 M 42 Unknown Homograft (2nd) 21 mm Predominant stenosis
2 M 22 4 Homograft (2nd) 20 mm Predominant stenosis
3 F 12 5 Homograft 18 mm Mixed dysfunction
4 M 20 8 Homograft (reconstructed) Mixed dysfunction
5 M 38 2.5 Homograft 23 mm Predominant stenosis
6 F 26 5 Homograft 24 mm Predominant stenosis
7 M 11 7 Homograft 19 mm Predominant stenosis
8 M 13 10 Homograft 16 mm Predominant regurgitation
9 M 71 34 Porcine valve conduit (unknown) Predominant stenosis
10 F 24 8 Homograft (unknown) Predominant regurgitation
11 F 15 8 Homograft 20 mm Predominant regurgitation
12 M 48 31 Homograft (unknown) Predominant regurgitation
RV, Right ventricle; PA, pulmonary artery.Cardiovascular Surgery c Volume 138, Number 1 85
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After PPVI, the invasively measured peak RVOT gradi-
ent, and RV-systemic pressure ratio fell acutely (RVOT
gradient 34  6 to 14  3 mm Hg, P< .01, RV–SP ratio
0.68  0.07 to 0.42  0.03, P< .01). Likewise, pulmonary
regurgitant fraction measured on cardiac MRI fell after
PPVI (20%  6% to 2%  1%, P< .05).
On cardiac MRI, the indexed RV end-diastolic volume
decreased (91  13 to 78  12 mL $ beat1 $ m2, P< .01;
Table 2). Other parameters did not show statistically signifi-
cant differences from before to after PPVI (Table 2).
Functional Outcome
CPEX testing revealed improved indices of maximal
cardiopulmonary exercise performance (peak oxygen
consumption 25.4  2.3 to 30.8  3.0 mL $ kg1 $ min1,
P< .01, maximum workload achieved 128  11 to 150 
13W, P<.01; Table 2). In addition, the anaerobic threshold
FIGURE 1. Angiographic appearance before (A) and immediately after
(B) successful percutaneous pulmonary valve implantation.86 The Journal of Thoracic and Cardiovascular Surincreased after restoration of RVOT function (13.6  1.3 to
15.0  1.3 mL $ kg1 $ min1, P< .05; Table 2).
Reintervention and Reoperation
During a mean follow-up of 18.8  4.6 months, 2 of 12
patients (17%) had further events. Both patients had
a good initial result from PPVI but had RVOT obstruction
recur because of stent fractures and were treated with second
PPVI at 4 and 7 months, respectively. Subsequently, 1 of the
2 patients required third PPVI at 3 years, when further hemo-
dynamically relevant stent fractures occurred. The other
patient had restenosis in the context of medically treated
endocarditis; however, the actual cause of restenosis could
not be unequivocally identified. This patient underwent
reoperation and device explantation at 13 months at another
institution. In this series, the probabilites of freedom from
RVOT reintervention were 81.5% at 1 and 3 years (Figure 2,
A), respectively, and the freedoms from RVOT reoperation
were 100% at 1 year and 90% at 3 years (Figure 2, B).
In all other patients (10 of 12, 83%), there was sustained
hemodynamic improvement at latest follow-up relative to
immediate postprocedural results. This improvement was
demonstrated by echocardiography, which also showed
preserved pulmonary valve competence (Table 3).
DISCUSSION
The search for the optimal surgical treatment for aortic
valve lesions in young patients remains a significant chal-
lenge. Ideally, a replacement valve should offer native
hemodynamic performance, the potential for adaptive
growth,2 freedom from anticoagulation therapy3 (which
has important implications for patient compliance), and
good longevity. In this respect, the autograft valve comes
close to the ideal, and it is superior to such other current
TABLE 2. Functional outcome
Parameter Before After P value
Cardiac magnetic resonance imaging
Pulmonary regurgitant fraction (%) 20  6 2  1 <.05
RV end-diastolic volume
(mL $ beat1 $ m2)
91  13 78  12 <.01
RV end-systolic volume
(mL $ beat1 $ m2)
41  10 34  11 .06
Effective RV stroke volume
(mL $ beat1 $ m2)
39  3 43  2 .11
RV ejection fraction (%) 59  4 62  5 .43
Cardiopulmonary exercise testing
Peak oxygen consumption
(mL $ kg1 $ min1)
25.4  2.3 30.8  3.0 <.01
Maximum workload (W) 128  11 150  13 <.01
Anaerobic threshold
(mL $ kg1 $ min1)
13.6  1.3 15.0  1.3 <.05
Respiratory exchange ratio 1.10  0.04 1.10  0.02 .95
All data are mean  SEM. RV, Right ventricle.gery c July 2009
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procedure continues to be questioned as a treatment option
for patients with aortic valve disease, however, because of
the potential for autograft dilatation or failure but in partic-
ular because of the need for RV-PA conduit. This study
showed PPVI to provide a novel, effective transcatheter
treatment strategy to prolong the lifespan of surgically
placed RV-PA conduits in this scenario. Such a minimally
invasive treatment for managing conduit dysfunction jus-
tifies a further review of the Ross procedure, particularly
for young patients, who probably benefit most from the ad-
vantages of the autograft option.
In this series, we had good procedural success and did
not see procedural complications with PPVI. This finding
is related to the advantageous anatomic substrate in patients
after the Ross procedure of circumferential RV-PA con-
duits placed into undistorted anatomy of the RVOT and
the PAs. These anatomic features compare favorably with
our experience with congenital right heart lesions10, in
which the underlying RVOT anatomy often makes device
implantation challenging, and in very rare cases even im-
possible. From a technical perspective, most patients with
FIGURE 2. A, Freedom from right ventricular outflow tract (RVOT) rein-
tervention was 81.5% at both 1 and 3 years. B, Freedoms from right ventric-
ular outflow tract reoperation were 100% at 1 year and 90% at 3 years.
PPVI, Percutaneous pulmonary valve implantation.The Journal of Thoracic andRV-PA conduit failure after the Ross procedure therefore
qualify for PPVI. Particular care should be taken to prevent
damage to the reimplanted coronary arteries, because their
proximal course could be at risk from external compression
during percutaneous valve deployment, although we have
not seen this in our own experience. Careful preprocedural
imaging assessment of the reimplanted coronary arteries in
relation to the RVOT should therefore be performed. This
imaging should involve noninvasive 3-dimensional imag-
ing modalities (eg, cardiac magnetic resonance or com-
puted tomography) in addition to standard angiography
during catheterization.
Importantly, RVOT function was restored in all patients
after PPVI, with significant reductions in pulmonary steno-
sis and regurgitation. A slight residual gradient across the
RVOT may be found with this technique, however, because
the device cannot always be expanded to its intended dimen-
sions as a result of the varying geometry and distensibility
of the failed RV-PA conduits (eg, the impact of asymmet-
ric calcifications). The mean size of the original RV-PA
conduits in this series revealed no evidence supporting
patient–prosthesis mismatch; nonetheless, this possibility
cannot be fully excluded. It is important to note that use of
the current device is restricted to RV-PA conduits larger
than 14 3 14 mm11 to achieve a sufficient valve orifice
area. Therefore, patients who have received RV-PA conduits
smaller than the suggested dimension (eg, those operated on
at a very young age) thus do not qualify for PPVI. In our
overall experience of PPVI, prestenting with bare-metal
stents and postdilatation with high-pressure balloons has
resulted in less residual gradients, leading to lower reinter-
vention rates.11
The restoration of RVOT function was accompanied by
changes in MRI and CPEX parameters, suggesting an objec-
tive improvement in cardiac function after relief of adverse
RV loading conditions.12 These data represent the first de-
scription of early functional outcome after RVOT reinter-
vention in the Ross population without the confounding
effects of cardiopulmonary bypass. Long-term ventricular
response and other outcome parameters, however, cannot
be foreseen at present.
TABLE 3. Echocardiographic follow-up
Peak RVOT
gradient (mm Hg)
Pulmonary
regurgitation
Preoperative 55.6  7.8 2.2  0.5
Postoperative 33.0  3.0 0.4  0.3
Latest follow-up 40.2  5.9 0.5  0.2
P value
Preoperative vs
postoperative
<.05 <.05
Postoperative vs
follow-up
.50 .88
All data are mean  SEM. RVOT, Right ventricular outflow tract.Cardiovascular Surgery c Volume 138, Number 1 87
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PPVI was recurrent RVOT obstruction. Overall, 3 repeated
PPVI were performed in 2 patients and was an effective
treatment option for early device failure caused by stent frac-
ture, the most common follow-up complication in our expe-
rience,13 resulting in further prolongation of the lifespan of
surgically placed conduits.14 RVOT reoperation was per-
formed in 1 patient, 13 months after PPVI. The surgery
was performed at another institution for what was described
as restenosis after medical treatment of endocarditis, al-
though the actual cause of the gradient across the device
could not be unequivocally identified at surgery.
Limitations
Our study highlights an important treatment option for pa-
tients after the Ross procedure; however, it represents a retro-
spective analysis in a relatively small patient population.
Most patients were referred to us from different institutions.
All follow-up investigations were performed and read in an
unblinded fashion. Although our study has demonstrated
immediate functional benefits from this procedure, its
long-term utility remains to be investigated.
CONCLUSIONS
RV-PAconduit dysfunction after theRossprocedure can be
successfully treatedwithPPVI. Thismayhelpdecrease the cu-
mulative surgical burden in the lifetime management of left
ventricular outflow tract lesions and thus justifies a further re-
view of the Ross operation, particularly for young patients.
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